Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

Agios’ stock drops after disclosing new liver-related safety warning in filing to FDA

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 10, 2024

Cytokinetics lifts curtain on Phase 3 aficamten data, commercial launch prep underway

Cytokinetics detailed results on Monday from a late-stage trial of aficamten for a rare heart disease, and the company is already hiring medical affairs and

May 14, 2024

‘I felt like I was dying’: How women with postpartum depression fall through the cracks of U.S. health care

Five and a half months after Kristina Dulaney had her second daughter, she developed postpartum psychosis. One day, she spontaneously quit her job as a

June 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.